Ultimate magazine theme for WordPress.
BTC
$5,277.68
-1.22%
ETH
$169.57
-2.63%
LTC
$76.34
-6.49%
DASH
$121.40
-2.08%
XMR
$68.45
-2.21%
NXT
$0.03
0%
ETC
$5.88
-5.62%
DOGE
$0.00
-3.88%
ZEC
$67.57
-2.06%
BTS
$0.06
0%
DGB
$0.01
+10.57%
XRP
$0.32
-2.7%
BTCD
$13.26
PPC
$0.56
0%
CRAIG
$0.00
XBS
$2.00
0%
XPY
$0.01
0%
PRC
$0.00
0%
YBC
$949.58
0%
DANK
$0.00

Bristol-Myers Squibb Co. to Collaborate With FameWave for Non-Small Cell Lung Cancer Study

362

FameWave Ltd., a privately held group developing CM-24, which is being acquired by Kitov Pharma Ltd. (KTOV), disclosed early Friday a clinical collaboration with Bristol Myers Squibb Company (BMY), pushing shares of Kitov by more than 18% in the pre-market.

Shares of Bristol Myers were up 0.7% in the pre-market.

The collaboration is to evaluate the combination of CM-24, FameWave’s monoclonal antibody targeting the novel immune checkpoint carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), with nivolumab (Opdivo), a PD-1 inhibitor, in patients with non-small cell lung cancer (NSCLC).

FameWave and Bristol Myers Squibb will coordinate on the protocol design for the phase 1/2 clinical trial. Under the terms of the deal, FameWave will fund and sponsor the study and Bristol Myers Squibb will supply nivolumab.

The “collaboration is a crucial step to begin evaluation of CM-24 in combination with a PD-1 inhibitor,” said Michael Schickler, CEO of FameWave. “We look forward to evaluating CM-24 in NSCLC since we believe it has a great potential as a novel immune checkpoint to be used in combination therapies for a variety of hard-to-treat cancers.”

Comments